Epstein Secrets

Monday, March 3 refused to fully throw out a class-action suit implicating the company. Gilead, along with Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson, have been accused of restricting competition in the HIV drug market, which is dominated by Gilead. [Continue Reading] ENVIRONMENT The Ariz

rch 3 refused to fully throw out a class-action suit implicating the company. Gilead, along with Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson, have been accused of restricting competition in the HIV drug market, which is dominated by Gilead. [Continue Reading] ENVIRONMENT The Arizona Rep

J). [Continue Reading] Life Sciences Intellectual Property Review: "Gilead to face HIV antitrust claims," Rory O'Neill, March 05, 2020, 11:30 AM Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March

g lawmakers that there would be four stages, with a minimum of five weeks between each stage." The AP (2/22, Lawless, Kirka) EFTA00148066 reports Johnson "said the government's plan would move the country 'cautiously but irreversibly' out of lockdown," with June 21 scheduled to kick off "the final sta

theories." FDA Outlines Fast Path For New Vaccines, Booster Shots To Cover New Virus Variants. Bloomberg (2/22, Langreth, Cortez, 3.57M) reports, "Drugmakers won't have to perform massive trials for new vaccines or booster shots developed to combat worrisome new variants of the coronavirus," the FDA said

U.S. targets, according to cybersecurity experts, and could fuel calls for a ban on such payments." ABC World News TonightVi (5/15, story 5, 0:32, Johnson, 3.64M) broadcast in another story companies are paying up in ransomware attacks at an increasing rate. The story said, "A recent report found that

at their own pace, those who need easier access to a vaccine and those under 30 who are open to getting a shot but not rushing to." EFTA00160783 Drugmakers Sponsoring Ads Seeking To Address Vaccine Hesitancy. The Wall Street Journal (5/16, Walker, Subscription Publication, 8.41M) reports the drugmakers